Overview
- PhRMA said Steve Ubl will leave by year’s end and will stay in the role until a new chief executive is named to ensure a smooth handover.
- The board chaired by Merck CEO Rob Davis will run the search, with Davis praising Ubl’s leadership and transition plan.
- Ubl has led the trade group since 2015, guiding it through the COVID-19 response and high-profile fights over drug prices, market access, and regulation.
- PhRMA represents major brand-name drugmakers and serves as their primary lobbying voice on issues like Medicare drug policy and FDA oversight.
- The succession will be closely watched for signs of any shift in industry strategy as debates over U.S. drug pricing and coverage rules continue.